Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials

BACKGROUND/OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Interstitial lung disease (ILD) is an extra-articular manifestation of RA. We investigated incidence rates of ILD in patients with RA, receiving tofacitinib 5 or 10 mg twice daily, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Citera, Gustavo, Mysler, Eduardo, Madariaga, Hugo, Cardiel, Mario H., Castañeda, Oswaldo, Fischer, Aryeh, Richette, Pascal, Chartrand, Sandra, Park, Jin Kyun, Strengholt, Sander, Rivas, Jose L., Thorat, Amit V., Girard, Tanya, Kwok, Kenneth, Wang, Lisy, Ponce de Leon, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612919/
https://www.ncbi.nlm.nih.gov/pubmed/32826657
http://dx.doi.org/10.1097/RHU.0000000000001552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612919/
https://www.ncbi.nlm.nih.gov/pubmed/32826657
http://dx.doi.org/10.1097/RHU.0000000000001552

Ejemplares similares